FDA approves esketamine treatment for MDD, suicidal ideation
Mental Health Weekly August 10, 2020 DOI: 10.1002/mhw.32471 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Intervention | Esketamine |
| Topics | Depression Esketamine |
| Key points | The FDA approved an expanded indication for SPRAVATO (esketamine) nasal spray to treat major depressive disorder with acute suicidal ideation or behavior, in addition to its existing approval for treatment-resistant depression. |
Abstract
The Food and Drug Administration (FDA) announced Aug. 3 approval of Janssen Pharmaceutical's supplemental new drug application (sNDA) for the expanded use of SPRAVATO esketamine Clll nasal spray for the treatment of major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO was initially approved by the FDA March 5, 2019, for the treatment of treatment‐resistant depression.